Please type a plus sign (+) inside this box -> +

Approved for use through 09/30/2000. OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

(	Application Number	10/031,037				
TRANSMITTAL	Filing Date	May 13, 2002				
FORM	First Named Inventor	Stephen Douglas Barrett, et al.				
(to be used for all correspondence after initial filing)	Group Art Unit	1614				
	Examiner Name					
Total Number of Pages in This Submission 32	Attorney Docket Number	A0000102-01-SMH				
ENCLOSURES (check all that apply)						
Fee Transmittal Form  Fee Attached  Drawing  Amendment / Response  Licensin  After Final  Affidavits/declaration(s)  Extension of Time Request  Express Abandonment Request  Information Disclosure Statement  Information Disclosure Statement	ng-related Papers  Routing Slip (PTO/SB/69) companying Petition  to Convert to a onal Application of Attorney, Revocation of Correspondence	After Allowance Communication to Group  Appeal Communication to Board of Appeals and Interferences  Appeal Communication to Group (Appeal Notice, Brief, Reply Brief)  Proprietary Information  Status Letter  Additional Enclosure(s) (please identify below):  Supplemental Information Disclosure Statement Statement as Provided by 37 CFR 1.97(b)  Return Postcard				
Response to Missing Parts under 37 CFR 1.52 or 1.53						
SIGNATURE OF APPLI	ICANT, ATTORNEY, OR A	AGENT				
Firm or Individual name Suzanne M. Harvey						
Signature Suzanne M Warwey						
Signature Suzanne M Warvey  Date Tebruary 20, 2003						
CERTIFICATE OF MAILING						
I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Assistant Commissioner for Patents, Washington, D.C. 20231 on this date:						
Typed or printed name Linda A. Zerby						
Signature Barda V.2	Date	2/25/2008				

Burden Hour Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be send to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



TECH CENTER 1600 2000 A0000102-01-SMH

## IN THE UNITED STATES PATENT & TRADEMARK OFFICE

PLICANT: Stephen Douglas Barrett, et al.

**EXAMINER:** 

SERIAL NO. : 10/031,037

**ART UNIT** 

: 1614

**FILED** 

: May 13, 2002

PAPER NO

FOR

: METHOD FOR TREATING CHRONIC PAIN USING MEK INHIBITORS

## Statement as Provided by 37 CFR 1.97(b)

Commissioner for Patents Washington, D.C. 20231

Dear Sir:

The Applicants submit that a Supplemental Information Disclosure Statement submitted herewith is being filed within three months of the filing of a national application other than a continued prosecution application under 37 CFR 1.53(d); within three months of the date of entry of the national stage as set forth in 37 CFR 1.491 in an international application; before the mailing of the first Office Action on the merits, or before the mailing of a first Office Action after the filing of a request for continued examination under 37 CFR 1.114.

As such, the Applicants respectfully request consideration of the enclosed Supplemental Information Disclosure Statement and request that all references cited herein be printed on the face of the patent upon grant of the Application.

It is understood by the Applicants that this paper requires no fee; however, authorization is given to charge any necessary filing fees and any additional fees or credit any overpayment to Deposit Account 23-0455.

Respectfully submitted,

Dated: Tebruary 20, 20

Suzanne M. Harvey

Registration No. 42,640

Warner-Lambert Company LLC

2800 Plymouth Road Ann Arbor, MI 48105

Telephone: (734) 622-2658 Facsimile: (734) 622-2928

	A		
Please type a	a plus sign (+) inside this box	<b>→</b>	+

(7

Sheet

PTO/SB/08B (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U. S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

1

Complet if Known		
Application Number	10/031037	
Filing Date	May 13, 2002	
First Named Inventor	Stephen Douglas Barrett, et al.	
Group Art Unit 1614		
Examiner Name		
Attorney Docket Number	A0000102-01-SMH	

	т —	OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS	_
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	Ţ²
		ALESSI, Dario R., et al., "PD 098059 Is a Specific Inhibitor of the Activation of Mitogen-activated Protein Kinase Kinase in Vitro and in Vivo", J. Biol. Chem., 1995, pp 27489-27494, Vol. 270, No. 46	
		HWANG, Daniel, et al., "Expression of Mitogen-Inducible Cyclooxygenase Induced by Lipopolysaccharide: Mediation through both mitogen-activated protein kinase and NF-KB signaling pathways in macrophages", Biochem Pharm, 1997, pp 87-96, Vol. 54, Issue 1	
		LARRIVEE, Jean-François, et al., "Role of the Mitogen-Activated Protein Kinases in the Expression of the Kinin B1 Receptors Induced by Tissue Injury ", J Immunol, 1998, pp 1419-1426, Vol. 160, No. 3	
		POLAKIEWICZ, Roberto D., et al., "A Mitogen-activated Protein Kinase Pathway Is Required for μ-Opioid Receptor Desensitization", J. Biol. Chem., 1998, pp 12402-12406. Vol. 273, No. 20	
		RECEIVEL	1
	_	FEB 2 8 2003	
		TECH CENTER 1600/2	90
	1		1

Examiner	Date
Signature	Considered

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>&</sup>lt;sup>1</sup> Unique citation designation number. <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.



